10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Monday, September 14, 2009

Aurobindo Pharma Ltd:Future growth prospects and outlook

Scripscan:Aurobindo Pharma Ltd

Story:Aurobindo pharma, head quartered in Hyderabad, manufactures generic pharmaceuticals, APIs and Intermediariers. Aurobindo is the largest Active Pharmaceutical Ingredients manufacturer in India under FDA approved facility. It has a presence in key therapeutic segments like antiretrovirals, CNS, cardio-vascular, gastroenterology, SSPs, cephalosporins, etc. The company is marketing products globally, in over 125 countries.High-end Vertically Integrated operations Aurobindo Pharma has high-end vertically integrated operations, which helps company to execute its key projects in recorded time and also to emphasize on regulated markets.Aurobindo has diversified product portfolio focusing on therapeutic areas like CNS, CVS, antiretrovirals, cephalosporins, diabetology, etc. The global market size of Aurobindo’s product pipeline (patented + generic) stands at US$209 billion whereas the share of US, EU and ROW is 49%, 25% and 26% respectively.Aurobindo pharma would experience majority of its growth from the US market mainly due to strong pipeline of products, huge generic opportunity and increasing customer base. We expect that the revenue from the US market would witness a robust growth rate of more than 60% during FY09-FY11E.Aurobindo has diversified its stream of business, which includes sale of dossier and supply arrangements thereby. In this the company sales dossiers to different pharma companies for which in return Aurobindo has been receiving milestone income for the same. Subsequently these supply arrangements would increase and drive the capacity utilization for the company. Aurobindo has entered into agreements with Pfizer for dossier licensing and supply arrangements. We expect that going forward Aurobindo would enter into more such arrangements and thus significantly driving the revenue.We have positive view on the company mainly due to attractive valuations and positive factors that justify the growth. We believe the valuations of the company to improve further mainly due to improving business mix and stability. The strong diversified pipeline of products clearly reflects the growth visibility.At the current market price of Rs 700 the company is trading at 8.3x FY10E EPS of Rs 85. and 5.3x FY11E EPS of Rs 133.We have valued the company using earnings multiple. We maintain our BUY recommendation with a target price of Rs 942, implying an upside potential of 33.2%. At the target price, the stock would be valued at 11x FY10E EPS of Rs 85.7.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner